-+ 0.00%
-+ 0.00%
-+ 0.00%

Clearmind Medicine files Japanese patent application for MEAI-based depression treatment

PUBT·05/29/2026 12:35:52
Listen to the news
Clearmind Medicine files Japanese patent application for MEAI-based depression treatment
  • Clearmind Medicine filed a Japanese patent application covering MEAI-based compositions for treating depression.
  • The filing expands the company’s intellectual property portfolio for its flagship non-hallucinogenic neuroplastogen-derived molecule.
  • Clearmind is developing MEAI across additional indications, including alcohol use disorder, weight loss, and other mental disorders.
  • Japan has about 3 million diagnosed cases of major depressive disorder, supporting a sizeable target market for new therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-062449), on May 29, 2026, and is solely responsible for the information contained therein.